MC
TVTX icon

Maverick Capital’s Travere Therapeutics TVTX Stock Holding History

Maverick Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-148,661
Closed -$3.33M – 146
2016
Q3 		$3.33M Buy
+148,661
New +$2.83M 0.04% 42

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maverick Capital's TVTX Position: Q4 2016 in Review

Maverick Capital sold out of Travere Therapeutics (TVTX) in Q4 2016, closing a stake of 148,661 shares — an estimated $3.33M sold.

Maverick Capital first reported a position in TVTX in Q3 2016 and held it in 1 quarter. The position peaked at $3.33M in Q3 2016. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

  • Maverick Capital reported no remaining Travere Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Maverick Capital sold 148,661 Travere Therapeutics shares in Q4 2016, an estimated $3.33M.
  • Maverick Capital first reported a position in Travere Therapeutics in Q3 2016 and held it in 1 quarter.
  • Maverick Capital's Travere Therapeutics position peaked at $3.33M in Q3 2016.
  • 121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on Maverick Capital's 13F filing for Q4 2016, filed 14 Feb 2017.